© 2021 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
ARVO
Focusing on 24-month data of the PALADIN study
May 07, 2021
Dr Michael A. Singer speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
Injections offer relief for refractory severe noninfectious keratitis
May 07, 2021
Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.
Researchers target ocular blood flow, systemic organ blood flow in hemorrhagic shock
May 06, 2021
Non-invasive ocular blood flow measurement using laser speckle flowgraphy may be a new indicator of shock-related organ damage, investigators report.
Looking at 10 years of dry eye disease flares
May 06, 2021
Dr Christopher Starr discusses key points from his virtual ARVO 2021 presentation regarding dry eye disease flares, including a rapid readout assessment of 10 years' worth of world literature to analyze studies in which the inflammatory disease's condition are categorized.
Linking patient imaging to AAO IRIS Registry clinical data
May 06, 2021
Dr. Michael Mbagwu speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.
Looking at real-world trial data replication outcomes of AAO IRIS Registry data
May 06, 2021
Dr Theodore Leng discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.
Clinical results analyze dexamethasone implant effect on macular thickness
May 05, 2021
Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Diabetes and DR: Making progress in the global epidemic
May 05, 2021
During a presentation at the ARVO virtual meeting, Lloyd Paul Aiello, MD, PhD, explains that a key hurdle for diabetic retinopathy is the lack of patient awareness, which is a substantial contributor to non-adherence to eye care guidelines and poor outcomes.
Initial data from AGTC-501 subretinal gene therapy for X-linked RP demonstrates safety, efficacy
May 05, 2021
During an ARVO presentation, Paul Yang, MD, PhD, explained that in a clinical trial, investigators used an adeno-associated viral vector to deliver a normal functioning copy of the RPGR gene via subretinal injection.
Non-viral gene therapy eases treatment burden in wet AMD
May 03, 2021
EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.